Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
暂无分享,去创建一个
J. Cayuela | H. Dombret | A. Delannoy | P. Chevallier | X. Thomas | S. Hayette | O. Reman | N. Ifrah | P. Rousselot | P. Agapé | J. Ribera | O. Ottmann | M. Delord | M. Lafage‐Pochitaloff | E. Jourdan | D. Hoelzer | M. Coudé | C. Berthou | H. Pfeifer | R. Bassan | S. Glaisner | L. Sutton | A. Banos | M. Hunault | B. Lioure | F. Huguet | N. Gokbuget | C. Gambacorti Passerini | T. Leguay | C. Salanoubat | C. Bonmati | M. Alexis | J. Fernandes | A. Bornand | Laure Morisset | V. Robin | M. Lafage-Pochitaloff | L. Morisset | A. Delannoy
[1] C. Bloomfield,et al. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665 , 2016, Leukemia & lymphoma.
[2] X. Thomas,et al. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia , 2016, Drug design, development and therapy.
[3] L. Escoda,et al. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. , 2016, Leukemia research.
[4] Z. Estrov,et al. Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia , 2015, Cancer.
[5] M. Konopleva,et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. , 2015, The Lancet. Oncology.
[6] H. Kantarjian,et al. Monoclonal antibodies in acute lymphoblastic leukemia. , 2015, Blood.
[7] J. Cayuela,et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. , 2015, Blood.
[8] T. Brümmendorf,et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. , 2014, Blood.
[9] H. Kantarjian,et al. Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia , 2014, American journal of hematology.
[10] H. Kantarjian,et al. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. , 2014, American journal of hematology.
[11] Z. Estrov,et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. , 2013, Blood.
[12] J. Cortes,et al. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias , 2012, Expert opinion on pharmacotherapy.
[13] U. Dührsen,et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia , 2012, Leukemia.
[14] R. Foà,et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.
[15] R. Foà,et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis , 2011, Haematologica.
[16] R. Pieters,et al. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 , 2010, Leukemia.
[17] S. Mustjoki,et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. , 2008, Blood.
[18] E. Thiel,et al. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. , 2008, Blood.
[19] J. Downing,et al. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. , 2008, Genes & development.
[20] V. Meignin,et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. , 2007, American journal of respiratory and critical care medicine.
[21] U. Dührsen,et al. Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) , 2007, Cancer.
[22] R. Foà,et al. Gruppo Italiano Malattie Ematologiche dell ' Adulto ( GIMEMA ) acute lymphoblastic leukemia without additional chemotherapy : results survival in elderly Philadelphia chromosome – positive patients with Imatinib plus steroids induces complete remissions and prolonged , 2007 .
[23] H. Dombret,et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study , 2006, Leukemia.
[24] H. Dombret,et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia , 2006, Leukemia.
[25] Sante Tura,et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.
[26] A. Delannoy,et al. Acute lymphoblastic leukemia in the elderly. , 2002, The hematology journal : the official journal of the European Haematology Association.
[27] Odd Aalen,et al. Nonparametric Estimation of Partial Transition Probabilities in Multiple Decrement Models , 1978 .